Classification of individuals based on ex-vivo glatiramer acetate-induced interferon-γ and interleukin-4 response

Multiple Sclerosis Journal

Volumn 18, Issue 10, 2012, Pages 1484-1492

  Gilli, Francesca ^a,b   Navone, Nicole D ^a,b   Valentino, Paola ^a,b   Granieri, Letizia ^a,b   Perga, Simona ^a,b   Malucchi, Simona ^a,b   Bertolotto, Antonio ^a,b  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

^b SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Glatiramer acetate; interferon gamma; interleukin 4; nonresponsive patients; real time PCR; transcriptional response

Indexed keywords

GAMMA INTERFERON; GLATIRAMER; INTERLEUKIN 4; MESSENGER RNA;

ADOLESCENT; ADULT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PATIENT CODING; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PROGNOSIS; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84867029774     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458512440349     Document Type: Article

References (18)

1. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicentre, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995 ; 45: 1268-1276
2. Johnson KP, Brooks BR, Cohen JA, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998 ; 50: 701-708
3. Comi G, Filippi M, Wolinsky JS. European/Canadian multicentre, double blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging measured disease activity and burden in patients with relapsing multiple sclerosis. European/ Canadian Glatiramer Acetate Study Group. Ann Neurol. 2001 ; 49: 290-297
4. Comi G, Martinelli V, Rodegher M, et al. PreCISe study group. Affect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomized, double blind, placebo-controlled trial. Lancet. 2009 ; 374: 1503-1511
5. Chen M, Johnson KP, Martin R, et al. Sustained immunological effects of glatiramer acetate in patients with multiple sclerosis treated for over 6 years. J Neurol Sci. 2002 ; 15: 71-77
6. Farina C, Then Bergh F, Albrecht H, et al. Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells. Brain. 2001 ; 124: 705-719
7. Farina C, Wagenpfeil S, Hohlfeld R. Immunological assay for assessing the efficacy of glatiramer acetate (Copaxone) in multiple sclerosis. A pilot study. J Neurol. 2002 ; 249: 1587-1592
8. Ge Y, Grossman RI, Udupa JK, et al. Glatiramer acetate (Copaxone) treatment in relapsing-remitting MS: quantitative MR assessment. Neurology. 2000 ; 54: 813-817
9. Martinelli Boneschi F, Rovaris M, Johnson KP, et al. Effects of glatiramer acetate on relapse rate and accumulated disability in multiple sclerosis: meta-analysis of three double-blind, randomized, placebo-controlled clinical trials. Mult Scler. 2003 ; 9: 349-355
10. Valenzuela RM, Costello K, Chen M, et al. Clinical response to glatiramer acetate correlates with modulation of IFN-gamma and IL-4 expression in multiple sclerosis. Mult Scler. 2007 ; 13: 754-762
11. Ann Neurol. Polman CH Reingold SC Edan G, ed. 2011: 292-302.
12. Schumacker GA, Beebe G, Kibler RF, et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci. 1965 ; 22: 552-568
13. Paludan SR. Interleukin-4 and interferon-gamma: the quintessence of a mutual antagonistic relationship. Scand J Immunol. 1998 ; 48: 459-468
14. Malucchi S, Gilli F, Caldano M, et al. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology. 2008 ; 70: 1119-1127
15. Neuhaus O, Farina C, Yassouridis A, et al. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc Natl Acad Sci U S A. 2000 ; 97: 7452-7457
16. Weber MS, Hohlfeld R, Zamvil SS. Mechanism of action of glatiramer acetate in treatment of multiple sclerosis. Neurotherapeutics. 2007 ; 4: 647-653
17. Farina C, Theil D, Semlinger B, et al. Distinct responses of monocytes to Toll-like receptor ligands and inflammatory cytokines. Int Immunol. 2004 ; 16: 799-809
18. Liblau R. Glatiramer acetate for the treatment of multiple sclerosis: evidence for a dual anti-inflammatory and neuroprotective role. J Neurol Sci. 2009 ; 287: S17 - S23